Suppr超能文献

临床实践中的维生素D治疗。一种剂量并不适用于所有人。

Vitamin D therapy in clinical practice. One dose does not fit all.

作者信息

Ryan P J

机构信息

Osteoporosis Unit, Medway Maritime Hospital, Gillingham, Kent UK.

出版信息

Int J Clin Pract. 2007 Nov;61(11):1894-9. doi: 10.1111/j.1742-1241.2007.01477.x.

Abstract

INTRODUCTION

Vitamin D is given to most patients with osteoporosis particularly the elderly and those on bisphosphonates. The most widely advocated dose is 800 IU with or without calcium. Whether or not this enables all or most patients to become vitamin D replete in clinical practice is not established.

AIMS

This study investigated a large cohort of patients with osteoporosis attending a metabolic bone clinic to identify if those on vitamin D supplements were adequately treated and if those commenced on treatment developed normal vitamin D levels.

METHODS

Twenty-five hydroxy vitamin D measurements from new all patients attending a district general hospital metabolic bone clinic as part of their preclinic investigations was examined. It was noted as to whether or not they were taking calcium and or vitamin D supplements. Patients not on supplements but with a low baseline vitamin D were treated with supplements and then had a repeat measurement after at least 3 months to assess whether or not they were replete.

RESULTS

From the database of 1028 patients, 100 had preclinic and follow-up vitamin D levels. They were of average age 61 years (SD 12) with a mean baseline vitamin D of 26 nmol/l. The mean posttreatment level was 58 nmol/l (SD 25). Posttreatment vitamin D levels were < 60 nmol/l in 55%, < 50 nmol/l in 36%, < 40 nmol/l in 24% and < 30 nmol/l in 13% and < 20 nmol/l in 4%. In 41 patients on Calcichew D3 Forte two tablets per day pretreatment vitamin D was 24 nmol/l (SD 16) and posttreatment 62 nmol/l (SD 28). Of this subgroup posttreatment 41% were < 60 nmol/l, 27% < 50 nmol/l, 22% < 40 nmol/l and 10% < 30 nmol/l. Two hundred and ten patients on vitamin D treatment preclinic had a mean vitamin D level of 64 nmol/l (SD 28). One hundred and twenty-four patients already on two tablets of Calcichew D3 Forte per day had a mean of 68 nmol/l (SD 28) of whom 38% were < 60 nmol/l, 24% < 50 nmol/l, 16% < 40 nmol/l, 6% < 30 nmol/l and 3% < 20 nmol/l.

CONCLUSION

Vitamin D therapy with conventional treatment improves serum levels of 25 hydroxy vitamin D but still leaves some patients with significant insufficiency and therefore the same dose of vitamin D is not appropriate for all.

摘要

引言

大多数骨质疏松患者,尤其是老年人和服用双膦酸盐类药物的患者,都会补充维生素D。最广泛推荐的剂量是800国际单位,可搭配或不搭配钙补充剂。在临床实践中,这是否能使所有或大多数患者的维生素D水平恢复正常尚未明确。

目的

本研究调查了一大群在代谢性骨病门诊就诊的骨质疏松患者,以确定服用维生素D补充剂的患者是否得到了充分治疗,以及开始治疗的患者维生素D水平是否恢复正常。

方法

检查了一家地区综合医院代谢性骨病门诊所有新患者作为门诊前检查一部分的25羟维生素D测量值。记录他们是否正在服用钙和/或维生素D补充剂。未服用补充剂但基线维生素D水平较低的患者接受补充剂治疗,至少3个月后再次测量,以评估他们是否维生素D水平恢复正常。

结果

在1028例患者的数据库中,有100例患者有门诊前和随访时的维生素D水平。他们的平均年龄为61岁(标准差12),平均基线维生素D水平为26纳摩尔/升。治疗后的平均水平为58纳摩尔/升(标准差25)。治疗后维生素D水平<60纳摩尔/升的患者占55%,<50纳摩尔/升的占36%,<40纳摩尔/升的占24%,<30纳摩尔/升的占13%,<20纳摩尔/升的占4%。41例每天服用两片钙尔奇D3咀嚼片的患者,治疗前维生素D水平为24纳摩尔/升(标准差16),治疗后为62纳摩尔/升(标准差28)。在这个亚组中,治疗后41%的患者<60纳摩尔/升,27%<50纳摩尔/升,22%<40纳摩尔/升,10%<30纳摩尔/升。210例门诊前接受维生素D治疗的患者平均维生素D水平为64纳摩尔/升(标准差28)。124例已经每天服用两片钙尔奇D3咀嚼片的患者平均水平为68纳摩尔/升(标准差28),其中38%的患者<60纳摩尔/升,24%<50纳摩尔/升,16%<40纳摩尔/升,6%<30纳摩尔/升,3%<20纳摩尔/升。

结论

常规治疗的维生素D疗法可提高血清25羟维生素D水平,但仍有一些患者存在明显不足,因此相同剂量的维生素D并不适合所有患者。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验